The metabolic syndrome (MS) is influenced by genetic and environmental factors. Peroxisome proliferator-activated receptor delta (PPAR-delta), a transcription factor involved in lipid metabolism, is a candidate gene for the MS. Objective: We verified whether genetic variants in this gene are associated with the MS and whether dietary fatty acids interact with the À87T4C polymorphism. Methods: By direct sequencing, we identified 15 variants in the PPAR-delta gene and analyses were pursued with the À87T4C polymorphism for 340 subjects. Results: Metabolic variables were comparable among each genotype group. The À87T4C polymorphism, fat intake and the interaction accounted, respectively for 2.2, 1.9 and 1.5% of the variance in high-density lipoprotein cholesterol (HDL-C) levels (Po0.05) (age, sex and energy intake were included into the model). The total cholesterol/HDL-C ratio was also modulated by a gene-diet interaction and by the -87T4C polymorphism (Po0.05). No gene-diet interaction effects were observed for other features of the MS. The age-and sex-adjusted odds ratio (OR) of exhibiting three or more features of the MS when carrying the À87C allele was 0.62 (P ¼ 0.04) compared to -87T/T. However, in subjects consuming less than 34.4% of energy from fat (median of fat consumption), the OR in carriers of the À87C allele was of 0.42 (P ¼ 0.008). Conclusion: These data suggest that the PPAR-delta À87T4C polymorphism may be associated with a lower risk to exhibit the MS and this association is influenced by dietary fat intake.
Introduction
The metabolic syndrome (MS) is defined by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) as the presence of three of the following criteria: abdominal obesity, hypertriglyceridemia, hypoalphalipoproteinemia, hypertension and high fasting glucose levels. 1 The increased risk for cardiovascular disease and type 2 diabetes associated with the MS emphasizes the importance of studying its etiology. A diet high in fat as well as genetic susceptibility may account for the presence of this constellation of metabolic abnormalities.
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The peroxisome proliferator-activated receptor delta (PPAR-delta) is a member of the PPARs family and is expressed ubiquitously. 5 It has been shown that PPAR-delta is involved in the regulation of genes participating in lipid and lipoprotein metabolism 6,7 as well as in adipose tissue and muscle fatty acid oxidation. [8] [9] [10] Its role in cellular response to inflammation is also well characterized. 11, 12 As for PPARa and PPARg, fatty acids are natural ligands of PPARdelta. 13 A polymorphism in the 5 0 untranslated region of the PPAR-delta gene has been identified, the À87T4C polymorphism (also named þ 294T4C), 14, 15 and shown to be associated with the plasma lipid profile. 14, 16 Transient transfection assays revealed that the À87C allele has higher transcription activity suggesting a greater PPAR-delta activity. 14 This suggests that PPAR-delta may play a role in the etiology of the MS. However, this issue has not been addressed in human studies. The objectives of this study were first to identify genetic variants in the PPAR-delta gene and evaluate their association with the MS-related phenotypes. Secondly, we verified whether dietary fat intake interacts with the polymorphism to modulate features of the MS.
Methods

Subjects
The study sample originates from the Saguenay-Lac-St-Jean region, located in the North-eastern part of the province of Quebec. Subjects recruited through the Chicoutimi Hospital Lipid Clinic for whom a food frequency questionnaire (FFQ), DNA as well as a lipid/lipoprotein profile were available were eligible to participate to this study. Subjects were excluded if they were diagnosed with type 2 diabetes, type III dysbetalipoproteinemia, familial hypercholesterolemia and familial combined hyperlipidemia. Type 2 diabetes was diagnosed according to the American Diabetes Association criteria. 1, 17 A total of 340 subjects (241 men and 99 women) participated to this study. NCEP-ATPIII criteria 1 were used to classify subjects with the MS. Written consent was obtained from all participating subjects. The Medical Ethics Committee of Laval University and Chicoutimi Hospital Lipid Clinic approved the protocol.
Biological variables
Blood samples free of medications were obtained in the morning after a 12-h overnight fast from an antecubital vein into vacutainer tubes containing ethylenediaminetetraacetic acid. Blood samples were centrifuged within 1 h, and the plasma frozen (À801C) until analysis. Genomic DNA was extracted using the Qiagen extraction kit (San Francisco, CA, USA). Plasma cholesterol and triglyceride (TG) were measured using enzymatic assays. 18, 19 Low-density lipoprotein cholesterol (LDL-C) was calculated. 20 The high-density lipoprotein cholesterol (HDL-C) fraction was obtained after precipitation of LDL particles in the infranatant with heparin and MnCl 2. 18,21 Apolipoprotein (apo) B concentrations were measured in plasma by the rocket immunoelectrophoretic method of Laurell, 22 as previously described. 23 Serum standards were prepared and calibrated against reference sera obtained from the Center for Disease Control (Atlanta, GA, USA). Plasma glucose concentration was enzymatically measured. 24 Fasting insulinemia was measured by radioimmunoassay with polyethylene glycol separation. 25 Body weight, height and body mass index (BMI) were recorded. Waist circumference was measured according to the procedure recommended at the Airlie conference. 26 Resting blood pressure measurements were performed after the subjects had a 5-min rest in a sitting position, phases I and V of Korotkoff sounds being used for systolic and diastolic blood pressures, respectively.
DNA analysis
Genomic DNA was extracted using the Qiagen extraction kit (San Francisco, USA). The exons, the exon-intron splicing boundaries as well as the 5 0 and 3 0 regions of the human PPAR-delta gene were sequenced in 36 men with plasma total cholesterol and LDL-C levels higher than the population 75 e percentile to screen for DNA variants. Table 1 shows primers used to amplify each fragment. Primers were designed using the Primer 3.0 software available on the Whitehead Institute/MIT Center for Genome Research server (http:// frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Polymerase chain-reaction (PCR) conditions were as follows: reaction volume was 50 ml, 1 U of RedTaqDNA polymerase (Sigma, St-Louis, MO, USA), 5 ml of 10Â PCR buffer recommended by the manufacturer, 1.5 mM of MgCl 2 , 0.2 mM of deoxynucleoside triphosphates, 31.5 pM of each primer and 0.1 mg of genomic DNA. Betaine (1.2 ml) was added for amplifying fragment #1 (promoter-exon 1) and exon 6. For exon 3, 63 pM of each primer was added instead of 31.5 pM. The annealing temperature for each fragment is shown in Table 1 . Sequencing reactions were performed using BigDyeTerminator v3.0 cycle sequencing (ABI Prism, Applied Biosystems, Foster city, CA, USA) and the products were analyzed on ABI 3100 automated DNA sequencer (PE Applied Biosystems, Foster City, CA, USA). The gel files were processed using the ABI Prism3100 data collection software applied biosystem version 1.1 and ABI Prism DNA PPARD À87T4C, dietary fat and the metabolic syndrome J Robitaille et al sequencing analysis software (PE Applied Biosystems, Foster City, CA, USA), then assembled and analyzed using the STADEN preGap4 and Gap4 programs. Determination of the PPAR-delta -87T4C polymorphism in the entire cohort of 340 subjects was performed using a restriction fragment length polymorphism (RFLP)-based method as previously described by Skogsberg et al.
14 PCR products were digested with 5 U of Bsl I. Digestion products were electrophoresed through a 1.5% agarose gel, and stained with ethidium bromide. Apo E genotype was determined by PCR-RFLP, as described previously.
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Nutritional assessment A quantitative FFQ has been used to evaluate fat intake. A trained dietitian administered this FFQ of 48 items to the participants. The FFQ asked the subjects to recall average use over the last year. The frequency of food consumption was based on the number of times items were consumed per day, per week or per month. A common unit or portion size for each food was specified using food models. The dietitian also asked to the participant's additional information concerning quality and quantity of dietary fat if necessary. Variables not normally distributed (Total cholesterol/HDL-C ratio, insulin, BMI and TG) were log 10 transformed. Analyses of covariance (with age and sex or age, sex and BMI as covariates) were used to compare metabolic variables between each genotype group. Analyses were performed using codominant, dominant and recessive model. Gene-diet interactions were evaluated by analyses of covariance using the General Linear Model. The model included the PPAR-delta -87T4C polymorphism, fat intake, the interaction term and confounding variables (age, sex and energy intake). The source of variation in metabolic parameters was computed using the type III sum of squares. This sum of squares applies to unbalanced study designs and quantifies the effects of an independent variable after adjustment for all other variables included in the model. Multilogistic regression analyses were also performed to assess the association between the PPAR-delta -87T4C polymorphism and the probability to exhibit three or more characteristics of the MS as defined by the NCEP-ATPIII 1 according to the median of fat consumed (above or below 34.4% of energy from fat). The age-and sex-adjusted odds ratio (OR) of exhibiting three or more features of the MS when carrying the À87C allele was compared to -87T/T homozygotes. All the analyses were performed with SAS version 8.2 (SAS Institute, Cary, NC, USA). A P-value p0.05 was used to identify a statistically significant result.
Results
Molecular screening of the PPAR-delta gene revealed the presence of 15 variants (Table 2) . Among them, five were located in non-coding exons, seven were located in introns, one in the promoter region and two in coding exons. The allele frequency of these variants is shown in Table 2 . Analyses were further pursued with variants having an allele frequency above 10% in this population and for which a potential functional impact has been demonstrated. For that last reason, silent mutations were not selected despite being common in this study population. Association analyses were therefore pursued with the PPAR-delta À87T4C polymorphism.
The frequency of the PPAR-delta -87C allele was of 20.1%. The genotype distribution was in Hardy-Weinberg equilibrium (w 2 ¼ 0.005, P ¼ 1.00). Subjects' characteristics according to genotype groups are shown in Table 3 . According to the dominant model, fasting plasma insulin levels appeared to be lower in carriers of the -87C allele but this difference did not remain statistically significant after adjustment for age, sex and BMI. Otherwise, each MS feature was similar according to PPAR-delta À87T4C genotypes when tested in a dominant, codominant or recessive model. Because metabolic variables differed for men and women, data were also analyzed separately by sex. In men, metabolic phenotypes were similar in 87T/T homozygotes and -87C carriers. However, plasma HDL-C levels were higher in women carrying the -87C allele compared to -87T/À87T homozygotes (1.3470.44, n ¼ 40 vs 1.1070.41 for -87T/T, n ¼ 56, P ¼ 0.02) and the total cholesterol/HDL-C ratio was decreased in -87C carriers compared to -87T/T (5.7972.84, n ¼ 37 vs 7.9877.34, n ¼ 55, P ¼ 0.03). There was a significant genotype-sex interaction for HDL-C (P ¼ 0.01) and for the total cholesterol/HDL-C ratio (P ¼ 0.05). These results must however be interpreted with caution owing to the low number of women included in this study (n ¼ 99). In order to explore the potential gene-diet interaction effect between fat intake and the PPAR-delta À87T4C polymorphism, covariance analyses were performed (Table 4 ). In a model including the PPAR-delta À87T4C polymorphism, dietary fat intake, the interaction term, as well as age, sex and energy intake, the polymorphism, fat intake and the interaction explained 2.2, 1.9 and 1.5% of the variance in plasma HDL-C levels (P ¼ 0.004, 0.007 and 0.02), respectively. The polymorphism and the interaction explained 2.2 and 1.7% of the variance in the total cholesterol/ HDL-C ratio (P ¼ 0.006 and P ¼ 0.02), respectively. Inclusion of the apo E genotype and BMI did not alter the results. No gene-diet interaction effects were observed for other features of the MS.
In order to illustrate these interactions, genotype groups were further sub-divided on the basis of fat intake using the median value (34.4% of energy intake) as a cutoff point. Among carriers of the À87C allele, plasma HDL-C levels were lower in subjects who consumed more than 34.4% of energy from fat whereas in À87T/T homozygotes plasma HDL-C levels were similar irrespective of the amount of fat consumed (P-value for interaction ¼ 0.004) (Figure 1a ). Similar results were observed with the total cholesterol/HDL-C ratio. Carriers of the À87C allele who had a diet rich in fat had an increased ratio whereas in À87T/T homozygotes, the ratio was similar in both subgroups (P-value for interaction ¼ 0.05) (Figure 1b) .
The OR for the risk of exhibiting three or more features of the MS for carriers of the À87C allele is shown in Figure 2 . The OR is 0.63 (95% confidence intervals (CI): 0.40-0.98, P ¼ 0.04). After adjustment for the effect of age and sex, the OR remained unchanged (OR: 0.62, 95% CI: 0.40-0.97, P ¼ 0.04). The OR adjusted for age and sex was not significant in subjects consuming more than 34.4% of energy from fat (OR: 0.95, 95% CI: 0.50-1.79, P ¼ 0.87). However, in subjects consuming less than 34.4% of energy from fat, the OR of exhibiting the MS was of 0.40 (95% CI: 0.21-0.77, P ¼ 0.006).
Discussion
In light of the results obtained, it appears that carriers of the À87C allele may be at lower risk of developing the MS, particularly when consuming a diet low in fat. Furthermore, the results suggest that the amount of fat consumed may influence the relationship between the PPAR-delta À87T4C polymorphism and features of the MS as a significant interaction between the PPAR-delta À87T4C polymorphism and dietary fat intake was observed for the total cholesterol/ HDL-C ratio as well as for plasma HDL-C concentrations.
The frequency of the À87C allele was of 20.1% and was similar to the frequency observed in a sample of Korean subjects 15 and in a Scotland population with coronary heart disease (CHD) 16 but was slightly higher than that in healthy subjects from Sweden (15.6%). 14 Although these results must Abbreviations: BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PPAR, peroxisome proliferator-activated receptor. Results are expressed as means7s.d. Number of subjects is shown in parenthesis. P 1 value after adjustment for age and sex; results were similar after adjustment for age, sex and BMI. a P-value after adjustment for age, sex and BMI was P ¼ 0.06. Table 4 Source of variation for the total cholesterol/HDL-C ratio and plasma HDL-C levels
Total-cholesterol/HDL-C ratio % of variance P-value % of variance P-value Abbreviations: HDL, high-density lipoprotein cholesterol; NS, not significant; PPAR, peroxisome proliferator-activated receptor.
PPARD À87T4C, dietary fat and the metabolic syndrome J Robitaille et al be replicated in other cohorts, data from the present study suggest that the association between the PPAR-delta À87T4C polymorphism and plasma HDL-C as well as the total cholesterol/HDL-C ratio might be sex-specific, women showing a stronger association. Two previous studies performed by Skogsberg et al. 14, 16 have been performed with male subjects and found no association in one study and lower plasma HDL-C levels in À87C carriers in the other study. Another study performed by Shin et al. 15 showed no association with plasma HDL-C levels. Unfortunately, these data were not analyzed separately by sex. A greater PPARdelta activation by the binding of prostacyclin could explain partly the stronger effect seen in women as estrogens are potent stimulators of prostacyclin synthesis 28 and prostacyclin binds PPAR-delta with great affinity. 29 At this moment, few scientific evidences are available to better understand this potential sex-specific association.
Results from in vitro and animal studies have consistently suggested a potential protective role of PPAR-delta against the MS.
6-8,10,30 However, the role of PPAR-delta in the human MS has not yet been investigated. Data from the present study suggest a lower risk of exhibiting the MS in carriers of the À87C allele. Although carriers of the -87C allele seem to be at lower risk of exhibiting the MS, the CHD and type 2 diabetes risk does not seem to be influenced by the presence of this variant. 15, 16 Skogsberg et al. 16 observed that homozygous for the À87C allele showed a trend toward higher risk of CHD but this result did not reach statistical significance. However, these studies did not take into account dietary fat intake, a nutritional factor involved both in the activation of PPAR-delta and in the development of the MS. Gene-environment interactions with the À87T4C polymorphism have been previously investigated. 16 Neither alcohol intake nor smoking habits influenced the relationship between the PPAR-delta À87T4C polymorphism and risk of CHD in a case-control study of men. 16 In the present Figure 1 Interaction between the PPAR-delta -87T4C polymorphism and fat intake on plasma HDL-C levels (a) and the total cholesterol/HDL-C ratio (b). Fat intake is stratified according to the median value (34.4% of the energy intake). Black bars present subjects who consumed less than 34.4% of energy from fat whereas open bars present subjects who ate more than 34.4% of energy from fat. -87C carriers group together 14 -87 C/C and 109 -87 T/C. The number within each bar identifies each subgroup whereas the number above the s.e. indicates the significant difference with the corresponding subgroup. The mean7s.e. for each group is presented. Figure 2 OR, with 95% CI, of having three or more components of the metabolic syndrome for carriers of the À87C allele. The risk is shown for the whole group:
without adjustment (black circle, P ¼ 0.04); adjusted for the effect of age and sex (white circle, P ¼ 0.04). The OR adjusted for age and sex is shown in subjects consuming less than 34.4% of energy from fat (black triangle, P ¼ 0.008) and in subjects consuming more than 34.4% of energy from fat (black square, P ¼ 0.86).
PPARD À87T4C, dietary fat and the metabolic syndrome J Robitaille et al study, dietary fat intake influenced the relationship between the PPAR-delta À87T4C polymorphism and features of the MS. The interest for the interaction between the PPAR-delta À87T4C polymorphism and dietary fat intake is motivated by the high binding affinity of long chain fatty acids for PPAR-delta. 13 We observed that plasma HDL-C levels were higher and the total cholesterol/HDL-C ratio was lower in carriers of the À87C allele exposed to a low-fat diet. In addition, the risk of exhibiting the MS in carriers of the À87C allele was modulated by the amount of fat consumed. The protective effect for the MS seen for carriers of the -87C allele is observed mainly in individuals consuming less than 34.4% of energy from fat and this apparent protective effect is not observed in individuals consuming more than 34.4% of energy from fat. Wang et al. 30 observed, in a transgenic mouse model overexpressing PPAR-delta, a decreased adiposity in animals maintained on a standard diet. Conversely, when fed a high-fat diet, they were partially protected against the increase in plasma TG and weight gain. The mechanisms underlying these observations are unclear at this moment. Transient transfection assays performed by Skogsberg et al.
14 have demonstrated a higher transcription activity for the À87C allele suggesting a greater PPAR-delta activity. In addition, it has been previously shown that plasma HDL-C levels of db/db mice and obese rhesus monkeys increase after treatment with PPAR-delta agonists. 6, 7 The fatty acid utilization in the skeletal muscle could be enhanced in À87C carriers through a greater activation by PPAR-delta of genes involved in long chain fatty acids b-oxidation. 8, 10 Therefore, carriers of the À87C allele might be protected from deleterious effects of a highfat diet on the lipid metabolism in comparison to the general population. It has also been demonstrated by Oliver et al.
7
that PPAR-delta increases cholesterol efflux from macrophage, fibroblast and intestinal cells, in part through an increase in the expression of the ABCA1 reverse cholesterol transporter.
The association between the PPAR-delta À87T4C polymorphism and plasma HDL-C levels was seen only in subjects consuming a low-fat diet. As fatty acids are ligands of PPAR-delta, we should have found an association in the presence of a high-fat diet. Polyunsaturated fatty acids are preferred ligands over saturated fatty acids and the proportion of polyunsaturated fatty acids to saturated fatty acids (P:S ratio) in the present study was higher in subjects consuming less dietary fat (0.5870.25 for o34.4% of energy from fat; 0.4970.28 for 434.4%, P-value for difference ¼ 0.003) suggesting that the P:S ratio may have influenced the results. However, the interaction between the PPAR-delta À87T4C and the P:S ratio on features on the MS did not reach statistical significance (not shown). Furthermore, we cannot exclude the possibility of an interaction with other PPAR isoforms as fatty acids are ligands for all three PPARs, 13, 31 all PPARs exert their effect via shared metabolic pathways including lipid transport and metabolism. PPAR-delta is also expressed in tissues where PPARa and PPARg are expressed. In addition, we and others have observed gene-diet interactions with variants in PPARa and PPARg. [32] [33] [34] [35] [36] Features of the MS were modulated by an interaction effect between the PPARa L162V polymorphism and fat intake 32, 34, 36 and by the PPARg Pro12Ala polymorphism and fat intake. 33, 35 These results suggest that the effect of fat intake on the MS could be mediated through the activation of PPARs by fatty acids.
In conclusion, the results of the present study suggest that the PPAR-delta À87T4C polymorphism is associated with lower risk to exhibit the MS and this association is modified by the amount of fat from the diet. Although data from the present study require confirmation in other populations, these results emphasize the need to understand gene-diet interactions effect in the etiology of the MS.
